Properties (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
gptkb:DeCode_Genetics
gptkb:Immunex_Corporation Micromet Tularik |
| gptkbp:awards |
Best Places to Work
Fortune 500 company DiversityInc Top 50 Companies for Diversity Sustainability Index Leader Top_100_Global_Innovators |
| gptkbp:CEO |
gptkb:Robert_A._Bradway
|
| gptkbp:clinicalTrials |
Phase 1 trials for autoimmune diseases
Phase 2 trials for cancer Phase 3 trials for cardiovascular disease |
| gptkbp:communityInvolvement |
gptkb:Amgen_Foundation
Health and wellness programs STEM education initiatives Environmental sustainability efforts Volunteer_programs |
| gptkbp:drugInterdiction |
Biologics
Small molecules Biosimilars |
| gptkbp:employees |
~20,000
|
| gptkbp:founded |
1980
|
| gptkbp:founder |
gptkb:George_B._Rathmann
|
| gptkbp:headCoach |
~20,000_employees
|
| gptkbp:headquarters |
gptkb:Thousand_Oaks,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
AMGN
|
| gptkbp:industry |
Biotechnology
|
| gptkbp:market |
$140 billion (2021)
|
| gptkbp:partnerships |
gptkb:AstraZeneca
gptkb:Bristol-Myers_Squibb gptkb:Pfizer Novartis |
| gptkbp:products |
gptkb:Enbrel
gptkb:Neulasta Prolia Repatha |
| gptkbp:researchFocus |
Inflammation
Neuroscience Oncology Bone health Metabolic disorders Cardiovascular Rare diseases |
| gptkbp:revenue |
$25.42 billion (2020)
|
| gptkbp:stockSymbol |
gptkb:AMGN
|
| gptkbp:subsidiary |
gptkb:Onyx_Pharmaceuticals
Amgen_Technology KAI_Pharmaceuticals |
| gptkbp:website |
www.amgen.com
|